Stryker recommends more vigilant monitoring of patients with recalled hip implants

February 20, 2013 by MassDevice staff

Stryker's Australian division recommends regular blood tests and soft tissue imaging for all patients implanted with the now-recalled ABG II Modular metal-on-metal implants.

hip implant x-ray illustration

Stryker's (NYSE:SYK) Australian arm provided national health regulators with updated recommendations for monitoring patients who received the company's now-recalled ABG II Modular hip systems.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.